Peter A. LeWitt

Best Publications

• Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

  Christopher G. Goetz;Barbara C. Tilley;Stephanie R. Shaftman;Glenn T. Stebbins

  7786
  Citations

• Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.

  Christopher G. Goetz;Stanley Fahn;Pablo Martinez-Martin;Werner Poewe

  1614
  Citations

• Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial

  R. Holloway;I. Shoulson;K. Kieburtz;M. McDermott

  1262
  Citations

• AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

  Peter A LeWitt;Ali R Rezai;Maureen A Leehey;Steven G Ojemann

  750
  Citations

• Levodopa in the treatment of Parkinson's disease: current controversies.

  C. Warren Olanow;Yves Agid;Yoshi Mizuno;Alberto Albanese

  501
  Citations

• Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions

  D. A. Loeffler;J. R. Connor;P. L. Juneau;B. S. Snyder

  434
  Citations

• Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

  Peter A. LeWitt;Peter A. LeWitt;M. Guttman;James W. Tetrud;Paul J. Tuite

  406
  Citations

• A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains.

  James R. Connor;Brian S. Snyder;Paolo Arosio;David A. Loeffler

  405
  Citations

• Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.

  Peter A. LeWitt

  396
  Citations

• Levodopa for the Treatment of Parkinson's Disease

  Peter A. LeWitt

  380
  Citations

• Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.

  Ira Shoulson;David Oakes;Stanley Fahn;Anthony Lang

  343
  Citations

• Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

  Peter A. LeWitt;Kelly E. Lyons;Rajesh Pahwa

  332
  Citations

• The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  R S Burns;P A LeWitt;M H Ebert;H Pakkenberg

  307
  Citations

• A Randomized, Double-blind, Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events

  Richard B. Dewey;J. Thomas Hutton;Peter A. LeWitt;Stewart A. Factor

  302
  Citations

• Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.

  Mark Stacy;Annette Bowron;Mark Guttman;Robert Hauser

  282
  Citations

• Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement

  Alberto J. Espay;Peter A. LeWitt;Horacio Kaufmann

  276
  Citations

• Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders.

  D.A. Loeffler;P.A. LeWitt;P.L. Juneau;A.A.F. Sima

  269
  Citations

• Cognitive impairments in Parkinson's disease: Distinguishing between effort-demanding and automatic cognitive processes

  Herbert Weingartner;Stanley Burns;Rita Diebel;Peter A. LeWitt

  260
  Citations

• Reliability of a new scale for essential tremor

  Rodger Elble;Cynthia Comella;Stanley Fahn;Mark Hallett

  259
  Citations

• TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.

  C Warren Olanow;Anthony H V Schapira;Peter A LeWitt;Karl Kieburtz

  217
  Citations